



US009636486B2

(12) **United States Patent**
Consigny et al.

(10) **Patent No.:** **US 9,636,486 B2**

(45) **Date of Patent:** **May 2, 2017**

(54) **METHODS AND DEVICES FOR ELUTING AGENTS TO A VESSEL**

(71) Applicant: **Abbott Cardiovascular Systems Inc.**,
Santa Clara, CA (US)

(72) Inventors: **Paul M. Consigny**, San Jose, CA (US);
William E. Webler, San Jose, CA
(US); **Gustavo D. Cipolla**, San
Francisco, CA (US); **Gordon S.**
Stewart, San Ramon, CA (US);
Benjamyn Serna, Gilroy, CA (US);
Daniel L. Cox, Palo Alto, CA (US)

(73) Assignee: **Abbott Cardiovascular Systems Inc.**,
Santa Clara, CA (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/952,811**

(22) Filed: **Nov. 25, 2015**

(65) **Prior Publication Data**

US 2016/0074635 A1 Mar. 17, 2016

Related U.S. Application Data

(62) Division of application No. 14/053,456, filed on Oct.
14, 2013, now Pat. No. 9,216,027, which is a division
(Continued)

(51) **Int. Cl.**
A61M 25/10 (2013.01)
A61B 17/22 (2006.01)
A61M 25/00 (2006.01)

(52) **U.S. Cl.**
CPC **A61M 25/104** (2013.01); **A61B 17/22**
(2013.01); **A61M 25/10** (2013.01);
(Continued)

(58) **Field of Classification Search**

CPC A61M 2025/1081; A61M 2025/105; A61M
25/10; A61M 25/104; A61M 2025/0057;
(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,437,856 A 3/1984 Valli
4,693,243 A 9/1987 Buras
(Continued)

FOREIGN PATENT DOCUMENTS

EP 0511499 3/1992
EP 0567788 3/1993
(Continued)

OTHER PUBLICATIONS

Abbot Cardiovascular Systems, Non-Final Office Action mailed
Dec. 18, 2013 for U.S. Appl. No. 14/053,456.

(Continued)

Primary Examiner — Theodore Stigell

(74) *Attorney, Agent, or Firm* — Blakely Sokoloff Taylor
& Zafman; William Thomas Babbitt

(57) **ABSTRACT**

Systems, devices and methods for eluting an agent at a
treatment site are disclosed. The devices include an expand-
able frame and at least one membrane. The membrane may
carry an agent to elute at the treatment site. The membrane
may allow blood flow at the treatment site during agent
delivery.

5 Claims, 12 Drawing Sheets

